非病毒纳米颗粒体内工程化 CAR 免疫细胞

In vivo engineering of CAR immune cells by nonviral nanoparticles.

抗原结合亲和力是 CD5 CAR-T 细胞持久抗肿瘤活性的关键决定因素

Antigen-binding affinity is a key determinant of the durable antitumor activity of CD5 CAR-T cells.

CAR 在非 B 细胞恶性肿瘤中停滞了吗？我们身处何处，又将去向何方？

Have CARs stalled for non-B-cell malignancies? Where are we, and where are we going?

CD5 消融通过减轻耗竭和促进细胞毒性，增强工程化 T 细胞的持久性和抗肿瘤效力

CD5 ablation enhances persistence and antitumor potency of engineered T cells by mitigating exhaustion and promoting cytotoxicity.

这些集体发现确立了 CD5 消融作为规避当前 T 细胞疗法固有局限性的可行策略，为临床转化提供了机制依据。

使用 CRISPR/Cas9 技术生成抗 CD5 CAR 敲入的人诱导多能干细胞系

Generation of an anti-CD5 CAR knock-in human induced pluripotent stem cell line using CRISPR/Cas9 technology.

CAR-T 细胞治疗 T 细胞来源的血液系统恶性肿瘤

Chimeric antigen receptor-T cell therapy for T cell-derived hematological malignancies.

异基因 CD5 特异性 CAR-T 疗法治疗复发/难治性 T-ALL：一项 I 期试验

Allogeneic CD5-specific CAR-T therapy for relapsed/refractory T-ALL: a phase 1 trial.

CD5 缺失增强过继性 T 细胞治疗的抗肿瘤活性

CD5 deletion enhances the antitumor activity of adoptive T cell therapies.

mRNA 工程化 CD5-CAR-γδT(CD5-) 细胞用于 T 细胞急性淋巴细胞白血病的免疫治疗

mRNA-Engineered CD5-CAR-γδT(CD5-) Cells for the Immunotherapy of T-Cell Acute Lymphoblastic Leukemia.

微流控细胞转染装置整合至基因编辑 CAR-T 细胞生产流程的开发

Development of a microfluidic cell transfection device into gene-edited CAR T cell manufacturing workflow.